摘要
目的对卡维地洛治疗射血分数保留心力衰竭(HFp EF)的疗效及安全性进行Meta分析。方法计算机检索Pub Med、EMbase、The Cochrane Library、中国生物医学文献数据库、中国万方数据库、中国知网数据库,检索时间从建库截止到2016年12月,纳入卡维地洛治疗HFp EF患者疗效及安全性的随机对照实验,文献语种限定为中文和英文,提取相关资料,对纳入研究的方法学质量进行评价,用Rev Man5.3软件进行Meta分析结果纳入7个研究,共计667例患者。Meta分析结果显示:与对照组相比卡维地洛能改善HFp EF患者的临床心功能疗效(RR=1.29,95%CI:1.05~1.58,P=0.02)和显著改善左室舒张功能(E/A值:MD=0.20,95%CI:0.11~0.29,P<0.001)。结论卡维地洛能改善HFp EF患者心功能和左室舒张功能。
Objective To systematically review the efficacy and safety of carvedilol in the treatment of patients with heart failure with preserved ejection fraction（ HFp EF） by meta analysis. Methods A thorough literature search about studies on the relationship between carvedilol and Patients with heart failure with preserved ejection fraction was performed among Pub Med,Embase,Cochrane Library,CBM,WANFANG,CNKI database form inception to December2016.. Only Chinese and English language papers were included. Then relevant datas were extracted and the quality of studies was evaluated. Meta-analysis was performed by using Rev Man 5. 3 software. Results Seven randomized controlled trials involving 667 patients were included in the meta analysis. Compared with the control group,carvedilol resulted in a improvement of efficacy（ RR = 1. 29,95% CI： 1. 05-1. 58,P = 0. 02） and significant improvement of diastolic function in HFp EF patients（ E/A ratio： MD = 0. 20,95% CI： 0. 11-0. 29,P 〈 0. 001）. Conclusion Carvedilol can improve the heart and diastolic function in patients with HEp EF.
作者
陈宏
刘涛
邓诗武
侯霁芯
黄磊
王秋林
Chen Hong,Liu Tao,Deng Shiwu,Hou Jixin,Huang Lei,Wang Qiulin(Department of Cardiology,Xindu District People’s Hospital of Chengdu, Chengdu 610500, China)
出处
《中国临床保健杂志》
CAS
2018年第4期471-476,共6页
Chinese Journal of Clinical Healthcare
基金
四川省科技厅基金资助项目(2016SZ0052)
